| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
SIA Crosslinker targets amine and sulfhydryl groups on proteins. The N-hydroxysuccinimide (NHS) ester reacts with primary amines (e.g., lysine residues on antibodies) to form stable amide bonds. The iodoacetyl group reacts with sulfhydryl groups (e.g., cysteine thiols on antibodies or drug linkers) to form stable thioether bonds. This heterobifunctional reactivity enables sequential conjugation of two different molecules.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1].
SIA Crosslinker is used to prepare antibody-conjugated active molecules in ADC platforms. The compound enables stable and site-specific drug conjugation. Its non-cleavable nature ensures that the ADC remains intact in circulation, providing a stable linkage between the antibody and the payload. |
| ln Vivo |
SIA Crosslinker is typically used in in vitro conjugation reactions. It is not typically evaluated for in vivo activity as a standalone compound, but rather as a component of ADC synthesis. The resulting ADCs are evaluated in in vivo efficacy models. The non-cleavable nature of the SIA Crosslinker ensures stable conjugation, which can affect ADC pharmacokinetics and biodistribution.
|
| Enzyme Assay |
SIA Crosslinker is characterized using standard analytical techniques. The NHS ester reactivity with amines can be monitored by HPLC or LC-MS. The iodoacetyl group reactivity with thiols can be assessed by Ellman's assay (DTNB) to measure the disappearance of free thiols. Conjugation efficiency is determined by SDS-PAGE, SEC-HPLC, or MALDI-TOF mass spectrometry to confirm the formation of antibody-linker-drug conjugates.
|
| Cell Assay |
SIA Crosslinker is used to prepare antibody-drug conjugates (ADCs) in vitro. Antibodies are first reacted with SIA Crosslinker via the NHS ester to form antibody-linker intermediates. After purification to remove excess crosslinker, drug payloads containing free thiols (or thiol-containing linkers) are reacted with the iodoacetyl groups on the antibody to form the final ADC. Conjugation efficiency and drug-to-antibody ratio (DAR) are determined by HPLC or mass spectrometry.
|
| Animal Protocol |
SIA Crosslinker is not typically administered to animals as a standalone compound. Instead, ADCs synthesized using SIA Crosslinker are evaluated in in vivo models. These ADCs are administered intravenously to tumor-bearing mice at various doses. Tumor volumes and body weights are monitored. The non-cleavable nature of SIA Crosslinker ensures stable drug conjugation, which can influence ADC pharmacokinetics, efficacy, and toxicity.
|
| ADME/Pharmacokinetics |
SIA Crosslinker has a molecular weight of 283.02 and molecular formula C6H6INO4. It has a melting point of 148°C. The compound is soluble in DMSO (10 mM) and appears as a white to light yellow powder to crystal. Storage is recommended at -20°C. Purity is typically >95% or >99.3%. SIA Crosslinker is also known as N-Succinimidyl iodoacetate and Iodoacetic acid N-hydroxysuccinimide ester.
|
| Toxicity/Toxicokinetics |
SIA Crosslinker is a heterobifunctional, non-cleavable crosslinking reagent. It is used for amine-to-sulfhydryl conjugation in bioconjugate chemistry. The NHS ester reacts with primary amines, while the iodoacetyl group reacts with sulfhydryl groups. This enables targeted antibody modification and stable site-specific drug conjugation in ADC platforms. The compound is for research and manufacturing use only.
|
| References | |
| Additional Infomation |
No specific toxicology data is available for SIA Crosslinker as a standalone compound. However, as a reactive chemical containing an iodoacetyl group, it should be handled with appropriate precautions. Iodoacetamide derivatives are known alkylating agents and may be toxic if ingested, inhaled, or absorbed through skin. The compound is corrosive to metals. Standard laboratory safety practices should be followed, including the use of personal protective equipment.
|
| Molecular Formula |
C6H6NO4I
|
|---|---|
| Molecular Weight |
283.02014
|
| Exact Mass |
282.934
|
| CAS # |
39028-27-8
|
| PubChem CID |
3299230
|
| Appearance |
White to yellow solid powder
|
| Density |
2.1±0.1 g/cm3
|
| Boiling Point |
315.6±44.0 °C at 760 mmHg
|
| Melting Point |
148ºC
|
| Flash Point |
144.7±28.4 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.615
|
| LogP |
-0.76
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
224
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VRDGQQTWSGDXCU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H6INO4/c7-3-6(11)12-8-4(9)1-2-5(8)10/h1-3H2
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 2-iodoacetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5333 mL | 17.6666 mL | 35.3332 mL | |
| 5 mM | 0.7067 mL | 3.5333 mL | 7.0666 mL | |
| 10 mM | 0.3533 mL | 1.7667 mL | 3.5333 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
